What did the new review of GHK-Cu research find?

The August 2026 review found 20 eligible studies of GHK-Cu as a standalone aesthetic intervention. Eighteen were preclinical studies in cells or animals, and only two were randomized human trials. Both human trials tested topical use. The authors found a reasonable biological basis for more research but said larger, better-standardized clinical trials are needed.

Are there human trials of injectable GHK-Cu?

No randomized human trial of injectable GHK-Cu appeared in the 2026 systematic review. The two randomized human trials used topical products. Animal wound experiments included local administration, but an animal wound model cannot establish the benefits, appropriate dose, or safety of a prescription injection in people.

Do topical GHK-Cu studies prove injections work?

No. Topical and injectable use expose the body differently, so evidence from skin application cannot establish what an injection does. The topical trials reported limited cosmetic signals, including patient satisfaction and wrinkle measurements, but they did not answer questions about whole-body effects or the short- and long-term safety of injections.

What is GHK-Cu's regulatory status?

No. GHK-Cu is not FDA-approved, and compounded GHK-Cu does not go through FDA premarket review for safety, effectiveness, or quality. FDA plans an advisory discussion about GHK-Cu and the 503A bulks list before the end of February 2027. A licensed provider may still prescribe a compounded formulation; that decision belongs to the patient and doctor.

Why do the animal GHK-Cu studies matter?

They show that the idea is biologically plausible and help researchers choose what to test next. Rat wound studies found changes in collagen, water-binding tissue molecules, and selected remodeling enzymes. Those findings are useful for designing human trials, but they do not show that injectable GHK-Cu improves skin, healing, or how a person feels.

What should a provider explain before prescribing GHK-Cu?

The provider should separate topical human findings from animal and cell research, explain that no randomized injectable human trial was identified in the new review, and discuss what outcome would be monitored. The conversation should also cover medical history, the full compounded formulation, possible risks, and why that route is being considered.

GHK-Cu Studies Find a Gap in Human Evidence

GHK-Cu studies don't yet support the confident claims often made for injections. As of September 6, 2026, the day this article was written, a systematic review published August 20 found 20 eligible studies: 18 were preclinical, meaning they were done in cells or animals, and two were randomized human trials. Both human trials used GHK-Cu on the skin. No randomized human trial in the review tested injectable GHK-Cu.

That doesn't mean the compound does nothing. It means the strongest evidence and the route people often ask about don't line up yet.

What the new GHK-Cu studies review found

GHK-Cu is a peptide—a short chain of amino acids—that binds copper. Researchers have studied it because copper and GHK take part in processes involved in tissue repair.

The August 2026 Aesthetic Surgery Journal review used PRISMA, a standard checklist for finding and reporting evidence, and searched three medical databases through March 2026. It found exactly 20 eligible studies of GHK-Cu as a standalone aesthetic intervention.

Evidence found	Number	Route or setting	What it can answer
Preclinical studies	18	Cells or animals	Whether a mechanism is plausible
Randomized human trials	2	Topical	Limited questions about skin outcomes
Randomized injectable human trials	0	None	Nothing yet about benefits or safety in people

A randomized trial assigns treatments by chance, which helps separate a treatment effect from expectation and other differences between groups. Finding only two matters. The review's authors said the field still lacks standardized clinical guidance and needs larger trials with consistent formulations, doses, and delivery methods.

What the two human trials actually showed

The review reported two positive signals: greater patient satisfaction after laser resurfacing in one trial, and smaller wrinkle volume and depth than control in the other. Those findings are worth noticing. They are not broad proof of skin repair, anti-aging effects, or benefit from an injection.

The post-laser study makes that distinction especially clear. Thirteen people completed a randomized comparison of topical skin-care regimens after carbon-dioxide laser resurfacing. Computer analysis and blinded evaluators found no significant difference in redness, wrinkles, or overall skin appearance between groups. A questionnaire did favor the GHK-Cu group for satisfaction, with a P value of .04—a statistical measure suggesting the difference was unlikely to be random in that small study (Miller et al., Archives of Facial Plastic Surgery, 2006).

In plain terms, people liked the result more, but the objective measurements did not show that GHK-Cu caused better healing or appearance. With 13 completers and a topical regimen, the trial cannot tell us what an injection would do.

The newer review also reported reduced wrinkle volume and depth in a topical trial. Even taken at face value, that is a narrow cosmetic finding from skin application. It doesn't establish whole-body effects, an injectable dose, or long-term safety.

Why the laboratory findings still matter

The laboratory story is more developed. Researchers have looked at the extracellular matrix, the supportive material around cells. That includes collagen and glycosaminoglycans, water-binding molecules that help give tissue structure.

In a 1993 experiment, GHK-Cu was placed into wound chambers under the skin of rats. The treated chambers accumulated more collagen, total protein, and glycosaminoglycans as the concentration rose (Maquart et al., Journal of Clinical Investigation, 1993). This is often shortened online to “GHK-Cu builds collagen.” The missing half is that it happened in an artificial rat-wound model.

Another rat-wound study looked at matrix metalloproteinases, enzymes that help take apart and rebuild the tissue scaffold. GHK-Cu changed the timing and activity of selected enzymes during healing, while leaving one form of collagenase unchanged (Siméon et al., Journal of Investigative Dermatology, 1999). That suggests remodeling is more complicated than simply making more collagen.

These experiments give scientists a sensible reason to keep studying GHK-Cu. They don't supply a human clinical outcome. A local injection into a rat wound chamber is not the same thing as a prescription injection in a person.

KLOW is a blend rather than GHK-Cu alone. Its evidence has to be considered as a complete formulation; results about one ingredient cannot establish what the blend does as a whole. The KLOW product page explains how that option is presented.

Topical evidence does not answer the injection question

Route matters. A product applied to the skin is intended to act locally. An injection changes where the compound travels and what tissues are exposed. Evidence from one route cannot simply be carried over to the other.

The honest answer is that there is no published randomized human trial of injectable GHK-Cu in the 2026 review. That leaves basic questions unanswered: whether an injection produces a meaningful benefit, which outcomes should be measured, and what short- and long-term harms occur. The GHK-Cu side-effects guide looks at the known and theoretical safety questions without turning this evidence review into a risk list.

This is also why a mechanism is not a result. Collagen changes in a cell dish or a rat wound can help design a human trial. They cannot tell a person how they will feel or look. For the broader plain-language explanation of the compound, see what GHK-Cu does.

What the FDA is considering next

The FDA says its Pharmacy Compounding Advisory Committee will discuss GHK-Cu as a bulk drug substance being considered for the 503A bulks list before the end of February 2027. The 503A list concerns ingredients that may be used for patient-specific compounding under federal conditions. The committee makes recommendations; it does not issue the final agency decision (FDA meeting page).

The page names GHK-Cu generally. It does not say the coming discussion is specifically about an injectable formulation, so claims that an injectable agenda is confirmed go beyond the posted source.

GHK-Cu is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. FDA status and clinical evidence answer different questions, and neither should be stretched into the other.

What this evidence means in a real visit

A careful conversation starts with the route. Topical results can support a discussion about topical use, but they cannot promise what an injection will do. Preclinical findings explain why researchers are interested; they don't predict a personal result.

The GHK-Cu product page is a starting point for the prescription route. At Promise, a licensed provider reviews every request and not everyone qualifies. That review should account for the thin human evidence, the lack of an injectable randomized trial, medical history, and the full formulation being considered.